JP2019506841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506841A5 JP2019506841A5 JP2018528327A JP2018528327A JP2019506841A5 JP 2019506841 A5 JP2019506841 A5 JP 2019506841A5 JP 2018528327 A JP2018528327 A JP 2018528327A JP 2018528327 A JP2018528327 A JP 2018528327A JP 2019506841 A5 JP2019506841 A5 JP 2019506841A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- single variable
- immunoglobulin single
- variable domain
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 108060003951 Immunoglobulin Proteins 0.000 claims 22
- 102000018358 immunoglobulin Human genes 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 11
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197999.4 | 2015-12-04 | ||
| EP15197999 | 2015-12-04 | ||
| PCT/EP2016/079575 WO2017093478A1 (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113792A Division JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506841A JP2019506841A (ja) | 2019-03-14 |
| JP2019506841A5 true JP2019506841A5 (enExample) | 2019-04-25 |
| JP6728355B2 JP6728355B2 (ja) | 2020-07-22 |
Family
ID=54782606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528327A Active JP6728355B2 (ja) | 2015-12-04 | 2016-12-02 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
| JP2020113792A Withdrawn JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113792A Withdrawn JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Country Status (34)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017120287A (ru) | 2012-02-28 | 2018-11-15 | АйАрЭм ЭлЭлСи | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 |
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| MA54648A (fr) * | 2015-12-04 | 2021-11-10 | Boehringer Ingelheim Int | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11033636B2 (en) * | 2017-05-31 | 2021-06-15 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| MX2020005424A (es) | 2017-11-29 | 2020-12-03 | Univ Texas | Composiciones y metodos para terapia contra el cancer. |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| CN120623353A (zh) * | 2018-07-05 | 2025-09-12 | 瑟罗泽恩奥普瑞汀公司 | 多特异性wnt替代分子和其用途 |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| TW202104258A (zh) | 2019-03-29 | 2021-02-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗癌組合療法 |
| BR112021016520A2 (pt) | 2019-03-29 | 2021-10-26 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| US11434297B2 (en) | 2019-05-04 | 2022-09-06 | Inhibrx, Inc. | CD123-binding polypeptides and uses thereof |
| MA55910A (fr) * | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Immunothérapies ciblant cd123 |
| CA3147832A1 (en) * | 2019-08-14 | 2021-02-18 | Sachdev S. Sidhu | Antibodies that bind to lrp6 proteins and methods of use |
| CA3147827A1 (en) * | 2019-08-14 | 2021-02-18 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| AU2020355027A1 (en) | 2019-09-23 | 2022-04-21 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
| WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| WO2024147897A2 (en) * | 2023-01-05 | 2024-07-11 | Harpoon Therapeutics, Inc. | Trop2 targeting trispecific protein for treatment of cancer |
| CN116375851B (zh) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| US7622267B2 (en) * | 2006-05-30 | 2009-11-24 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods |
| EP2447558B1 (en) | 2006-06-08 | 2013-05-29 | NSK Ltd. | Method for manufacturing a drawn cup needle roller bearing having a seal ring |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN100428934C (zh) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン．ヴェー． | 血清タンパク質と結合可能なペプチド |
| ES2560532T3 (es) | 2007-11-02 | 2016-02-19 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) |
| CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
| US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
| EP3498731A1 (en) | 2009-12-23 | 2019-06-19 | ESBATech, an Alcon Biomedical Research Unit LLC | Method for decreasing immunogenicity |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| WO2011107507A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
| SG184033A1 (en) * | 2010-03-24 | 2012-10-30 | Genentech Inc | Anti-lrp6 antibodies |
| US9290573B2 (en) * | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
| KR20140001216A (ko) * | 2010-10-20 | 2014-01-06 | 제넨테크, 인크. | Wnt 경로를 조절하기 위한 방법 및 조성물 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| JP5949270B2 (ja) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム |
| EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
| MA54648A (fr) | 2015-12-04 | 2021-11-10 | Boehringer Ingelheim Int | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
-
2016
- 2016-12-02 MA MA054648A patent/MA54648A/fr unknown
- 2016-12-02 ES ES16808971T patent/ES2821099T3/es active Active
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/es unknown
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/zh active Active
- 2016-12-02 MX MX2018006760A patent/MX380414B/es unknown
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
- 2016-12-02 NZ NZ742037A patent/NZ742037A/en unknown
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/ja active Active
- 2016-12-02 UA UAA201807120A patent/UA122079C2/uk unknown
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en not_active Ceased
- 2016-12-02 KR KR1020187019053A patent/KR102802241B1/ko active Active
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/pt active Search and Examination
- 2016-12-02 MA MA43368A patent/MA43368B1/fr unknown
- 2016-12-02 RS RS20201124A patent/RS60823B1/sr unknown
- 2016-12-02 SI SI201630953T patent/SI3383425T1/sl unknown
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/hu unknown
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/da active
- 2016-12-02 HR HRP20201528TT patent/HRP20201528T1/hr unknown
- 2016-12-02 CA CA3006235A patent/CA3006235A1/en active Pending
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 PH PH1/2018/501155A patent/PH12018501155B1/en unknown
- 2016-12-02 AR ARP160103720A patent/AR106949A1/es unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/pl unknown
- 2016-12-02 PT PT168089712T patent/PT3383425T/pt unknown
- 2016-12-02 EA EA201891331A patent/EA201891331A1/ru unknown
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 TW TW105139826A patent/TWI734719B/zh active
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/lt unknown
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
-
2018
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/es unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/es unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/ar unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/ja not_active Withdrawn
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506841A5 (enExample) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| JP2018527919A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2016053091A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2017529067A5 (enExample) | ||
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2019511212A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2018508509A5 (enExample) | ||
| JP2018512856A5 (enExample) | ||
| FI4050034T3 (fi) | Cd3:een sitoutuvia vasta-aineita | |
| JP2018521638A5 (enExample) |